Anupam Rasayan India Ltd Q4 FY2022 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/pzpr5msoyt7y5vm7ze6vxd23.pdf

Key Takeaways


The Inventory Overhang

Vishal Thakkar: "Today, the problem is that whatever I say, where the world moves, none of us really know well and hence I don't want to guide or even allude or indicate to anything which tomorrow we will have a conversation on that again. So, just wait for a quarter or two, let the things settle down and then we can have a more..."

Tanfac: The Fluorination Platform


Contract Structure & Pricing Shift

Anand Desai: "As these products are under contract and all the contracts have a pass-through mechanism, every customer knows what prices they have agreed in the past year when we agreed on the price. In the meantime, there is a tolerance level for each price or each raw material price, and once that raw material tolerance is breached, we immediately inform the customer that this raw material price has breached now from the agreed ones and we would like to bring it to your notice, which is the mechanism built in within the contract."

Growth Engine & Diversification


Margins & Balance Sheet

Vishal Thakkar: "I would not want to be aggressive on my commitment here."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthContinue historical ~26% CAGR trajectoryOver next time period (multi-year)
CAPEX deployment₹250 crores for LOI-linked expansion; asset turn of 1.75x, ROCE of 20%FY23
LOI conversionLOIs under negotiation to conclude6 to 12 months
Peak revenue from new moleculesBulk and significant revenue from latter half of rampFY25–26
Inventory normalizationImprovement in inventory days to begin, assuming volatility reducesH2 FY23 (conditional)
Contract pricing shiftRemaining ~50% of customers to move to 6-month pricingNext few quarters
Tanfac CAPEX~₹50 crores for debottlenecking KF and HF capacityNext year
Fluorination topline$200–260 million potential, over and above LOI bookMedium to long term
Promoter debt repaymentPaid offOver next 3 years
Term debt unwindingUnwoundOver 5 years
Telecom/semiconductor validationValidation and pilot runs continuing~9 months (until next March/February)

Key Metrics

MetricQ4 FY22
Total revenues₹316.9 cr, +16% YoY
EBITDA including other revenues₹96.9 cr, +48% YoY
EBITDA margin31%, vs 26% in FY21
Profit after tax₹46.1 cr, +108% YoY
Total revenues (FY22 full year)₹1,081.1 cr, +29% YoY
EBITDA (FY22 full year)₹311.2 cr, +42% YoY
EBITDA margin (FY22 full year)29%, vs 26% in FY21
Profit after tax (FY22 full year)₹152.2 cr, +116% YoY
PAT margin (FY22 full year)14%, vs 8% in FY21
Life sciences segment revenue (FY22)₹954.3 cr, 90% of total revenue
Other specialty chemicals segment revenue (FY22)₹108.6 cr, 10% of total revenue
Revenue CAGR (FY18–FY22)26%
ROCE (FY22)12%, vs 9% in FY18
Installed capacity27,000 MT, >100% growth from 12,000 MT in FY18
Product offerings48, +92% from 25 in FY18
Number of customers68, from 53 in FY18
R&D scientists77, up from 66 in Q3 FY22
Top 10 customer revenue concentration80% of total revenue
LOI/contract total value₹2,600 cr over 5 years, peak annual revenue ~₹500 cr
FY23 CAPEX guidance₹250 cr, expected asset turn of 1.75x and ROCE of 20%
Working capital debt (year-end FY22)~₹200 cr
Tanfac stake acquired26%, 25% from Aditya Birla group for ₹148 cr plus 1% from public via open offer
Fluorination topline potential (medium to long term)$100–200 mn per annum
Solar power investment₹27 cr for 7.5 MW plant, adding to 12.5 MW commissioned earlier